NervGen Pharma Corp (NGEN) - Total Liabilities
Based on the latest financial reports, NervGen Pharma Corp (NGEN) has total liabilities worth CA$16.02 Million CAD (≈ $11.59 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NervGen Pharma Corp - Total Liabilities Trend (2017–2024)
This chart illustrates how NervGen Pharma Corp's total liabilities have evolved over time, based on quarterly financial data. See NervGen Pharma Corp short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
NervGen Pharma Corp Competitors by Total Liabilities
The table below lists competitors of NervGen Pharma Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eimskipafélag Íslands hf
IC:EIM
|
Iceland | Ikr370.17 Million |
|
Monarch Networth Capital Limited
NSE:MONARCH
|
India | Rs3.17 Billion |
|
Trigold Holdings Ltd
TWO:3709
|
Taiwan | NT$10.95 Billion |
|
Nongshim Holdi
KO:072710
|
Korea | ₩518.33 Billion |
|
NACCO Industries Inc
NYSE:NC
|
USA | $248.54 Million |
|
STEICO SE
XETRA:ST5
|
Germany | €228.46 Million |
|
China Tian Lun Gas Holdings Limited
F:TLJ
|
Germany | €9.27 Billion |
|
Relais Group Oyj
HE:RELAIS
|
Finland | €316.94 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down NervGen Pharma Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NervGen Pharma Corp (NGEN) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NervGen Pharma Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NervGen Pharma Corp (2017–2024)
The table below shows the annual total liabilities of NervGen Pharma Corp from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$16.91 Million ≈ $12.23 Million |
+10.92% |
| 2023-12-31 | CA$15.25 Million ≈ $11.03 Million |
+46.39% |
| 2022-12-31 | CA$10.41 Million ≈ $7.53 Million |
+865.99% |
| 2021-12-31 | CA$1.08 Million ≈ $779.87K |
+42.78% |
| 2020-12-31 | CA$755.07K ≈ $546.21K |
-18.28% |
| 2019-12-31 | CA$923.95K ≈ $668.37K |
+58.45% |
| 2018-12-31 | CA$583.11K ≈ $421.81K |
+513.40% |
| 2017-12-31 | CA$95.06K ≈ $68.77K |
-- |
About NervGen Pharma Corp
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more